Long-term safety study of Hsk44459 for Behçet's disease
Treatments studied
Part of Immune system & allergy clinical trials.
This study is for people with Behçet's disease who have already taken the study medicine (HSK44459) in an earlier trial. It continues to check how safe and effective the medicine is over a longer time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have already taken part in a previous study of this medication (HSK44459) for Behçet's disease and finished the treatment as planned.
- You should not have active Behçet's disease affecting major organs like the lungs, blood vessels, stomach or intestines, brain, or eyes that needs strong treatment.
- You must not have had a serious drug-related side effect in the earlier study that, in the doctor's view, makes continuing unsafe.
- You must not currently have hepatitis B, hepatitis C, or any other active liver disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, HSK44459, to see if it can reduce mouth ulcers in people with Behçet's disease. If you have frequent mouth sores from Behçet's, this treatment might help.
This study tests a new pill called Hemay005 for adults with Behçet's disease who have at least two mouth sores that need treatment beyond creams or rinses. It aims to see if the drug safely reduces mouth ulcers.
This study tests whether adding a blood thinner (rivaroxaban) to standard immune therapy is better than immune therapy alone for treating blood clots in the legs caused by Behçet's disease. It may help prevent clots from getting worse or recurring.
This Phase 2 trial tests tocilizumab and tofacitinib to see if they can better control vascular (blood-vessel) Behçet’s syndrome. It may help by lowering inflammation and reducing complications from aneurysms in the aorta or peripheral arteries.
This study compares two biologic medicines, adalimumab and tocilizumab, to see which works better for severe eye inflammation (uveitis) caused by Behçet's disease. Both are given as injections, and the goal is to improve vision and reduce eye damage.
This study tests if ustekinumab or apremilast can help control Behçet's disease symptoms like mouth and genital ulcers, skin sores, and joint pain. It may be an option if standard treatments haven't worked well.
Hear when a new Bechet's Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.